Applications of Ruthenium Complex in Tumor Diagnosis and Therapy

doi:10.3389/fphar.2018.01323

Paper

Applications of Ruthenium Complex in Tumor Diagnosis and Therapy

Published Nov 19, 2018 · Ke Lin, Zizhuo Zhao, Huaben Bo

Frontiers in Pharmacology

Q1 SJR score

120

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Ruthenium complexes are a new generation of metal antitumor drugs that are currently of great interest in multidisciplinary research. In this review article, we introduce the applications of ruthenium complexes in the diagnosis and therapy of tumors. We focus on the actions of ruthenium complexes on DNA, mitochondria, and endoplasmic reticulum of cells, as well as signaling pathways that induce tumor cell apoptosis, autophagy, and inhibition of angiogenesis. Furthermore, we highlight the use of ruthenium complexes as specific tumor cell probes to dynamically monitor the active biological component of the microenvironment and as excellent photosensitizer, catalyst, and bioimaging agents for phototherapies that significantly enhance the diagnosis and therapeutic effect on tumors. Finally, the combinational use of ruthenium complexes with existing clinical antitumor drugs to synergistically treat tumors is discussed.

Highly Cited

Study Snapshot

Ruthenium complexes show potential in tumor diagnosis and therapy by inducing tumor cell apoptosis, autophagy, and inhibition of angiogenesis, as well as serving as specific tumor cell probes and effective photosensitizers for phototherapies.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

Applications of Ruthenium Complex in Tumor Diagnosis and Therapy

References

Charge Separation

Charge separation properties are crucial for efficient photovoltaic devices, and this study presents various analytical methods for analyzing molecular electronic transitions induced by photon capture.

SynAggreg: A Multifunctional High-Throughput Technology for Precision Study of Amyloid Aggregation and Systematic Discovery of Synergistic Inhibitor Compounds.

SynAggreg is a high-throughput platform for studying amyloid aggregation and identifying synergistic inhibitor compounds, potentially improving treatments for fatal amyloidoses.

A ruthenium-platinum metal complex that binds to sarcin ricin loop RNA and lowers mRNA expression.

IT127 is a promising anticancer agent that effectively binds to sarcin ricin loop RNA and reduces mRNA expression, potentially offering a promising treatment for cancer.

Novel ruthenium(II) triazine complex [Ru(bdpta)(tpy)]2+ co-targeting drug resistant GRP78 and subcellular organelles in cancer stem cells.

The novel ruthenium(II) triazine complex 1 shows greater cytotoxic potential and reduced drug resistance in cancer stem cells, making it an effective chemotherapeutic agent.

An estrogen receptor targeted ruthenium complex as a two-photon photodynamic therapy agent for breast cancer cells.

Ru-tmxf shows enhanced cellular uptake and photodynamic therapy efficiency in breast cancer cells with high estrogen receptor expression, leading to cell death.

Citations

Metal-based molecules in the treatment of cancer: From bench to bedside

Metal-based drugs show promising anticancer potential, but fewer side effects are needed for their widespread use in clinical practice.

Ruthenium-Based Small-Molecule Complexes: A Promising Approach for Drug Discovery

Ruthenium-based complexes show promise for cancer therapy due to their unique redox properties, high selectivity, and remarkable chelation capabilities, making them promising candidates for personalized cancer treatments.

Synthesis and Evaluation of Cytotoxic Activity of RuCp(II) Complexes Bearing (Iso)nicotinic Acid Based Ligands

Both ruthenium(II) complexes bearing (Iso)nicotinic acid-based ligands show moderate to high cytotoxic activity against various cancer cell lines, with complex 1 showing greater cell death in A431 and MDA-MB 231 cell lines.

Ruthenium(II) Complex with 1-Hydroxy-9,10-Anthraquinone Inhibits Cell Cycle Progression at G0/G1 and Induces Apoptosis in Melanoma Cells

The new ruthenium complex with 1-hydroxy-9,10-anthraquinone inhibits cell proliferation and induces apoptosis in melanoma cells, offering potential as a promising cancer chemotherapeutic.

A Novel Substituted Benzo[g]quinoxaline-Based Cyclometalated Ru(II) Complex as a Biocompatible Membrane-Targeted PDT Colon Cancer Stem Cell Agent

RuL2 is a biocompatible membrane-targeted photodynamic therapy agent that effectively kills colon cancer stem cells, preventing tumor recurrence and metastatic progression.

Metabolic plasticity in pancreatic cancer: The mitochondrial connection

Targeting mitochondrial metabolism holds promise for advancing pancreatic cancer therapeutics, potentially improving treatment efficacy and patient outcomes.

Ruthenium-p-Cymene Complexes Incorporating Substituted Pyridine–Quinoline Ligands with –Br (Br-Qpy) and –Phenoxy (OH-Ph-Qpy) Groups for Cytotoxicity and Catalytic Transfer Hydrogenation Studies: Synthesis and Characterization

Ruthenium-p-cymene complexes with substituted pyridine-quinoline ligands show poor in vitro anticancer activity and catalytic transfer hydrogenation of benzophenone to benzhydrol.